Navicixizumab Plus Paclitaxel in Platinum-Resistant Ovarian Cancer
April 27, 2022 12:40 pmby Matthew Stenger
In a phase Ib study reported in the Journal of Clinical Oncology, Fu et al found that the combination of navicixizumab (a bispecific antiangiogenic antibody to VEGF and delta-like ligand 4) and paclitaxel showed activity in … Read more